Shattuck Labs Inc Market Cap ($244.26 Million)
Market Cap & Net Worth: Shattuck Labs Inc (STTK)
Shattuck Labs Inc market cap. Shattuck Labs Inc (NASDAQ:STTK) has a market capitalization of $244.26 Million ($244.26 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15520 globally and #3694 in its home market, demonstrating a -1.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shattuck Labs Inc's stock price $5.47 by its total outstanding shares 63279843 (63.28 Million). Also see how efficiently does Shattuck Labs Inc generate cash for how efficiently the company converts equity into cash flow.
Shattuck Labs Inc Market Cap History (2020–2026)
Shattuck Labs Inc market cap history from 2020 to 2026. Data shows change from $3.32 Billion to $346.14 Million (-18.79% CAGR). Check latest Shattuck Labs Inc stock price today for real-time trading data and today's change.
Index Memberships
Shattuck Labs Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #411 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1513 of 3165 |
Weight: Shattuck Labs Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Shattuck Labs Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shattuck Labs Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore STTK net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
13.38x
Shattuck Labs Inc's market cap is 13.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.32 Billion | $9.93 Million | -$35.44 Million | 333.85x | N/A |
| 2021 | $538.51 Million | $30.02 Million | -$44.97 Million | 17.94x | N/A |
| 2022 | $145.54 Million | $652.00K | -$100.56 Million | 223.23x | N/A |
| 2023 | $451.19 Million | $1.66 Million | -$87.30 Million | 272.29x | N/A |
| 2024 | $76.57 Million | $5.72 Million | -$75.41 Million | 13.38x | N/A |
Competitor Companies of STTK by Market Capitalization
Companies near Shattuck Labs Inc in the global market cap rankings as of November 4, 2026. Also see total assets of Shattuck Labs Inc for a full breakdown of the balance sheet.
Key companies related to Shattuck Labs Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Shattuck Labs Inc (2020–2026)
Market capitalization of Shattuck Labs Inc from 2020 to today. Between 2020 and today, Shattuck Labs Inc's market cap moved from $3.32 Billion to $ 346.14 Million, with a yearly change of -18.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $346.14 Million | +49.86% |
| 2025 | $230.97 Million | +201.65% |
| 2024 | $76.57 Million | -83.03% |
| 2023 | $451.19 Million | +210.00% |
| 2022 | $145.54 Million | -72.97% |
| 2021 | $538.51 Million | -83.76% |
| 2020 | $3.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Shattuck Labs Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.26 Million USD |
| MoneyControl | $244.26 Million USD |
| MarketWatch | $244.26 Million USD |
| marketcap.company | $244.26 Million USD |
| Reuters | $244.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more